315 related articles for article (PubMed ID: 12106588)
21. Differential physiological effects of a low dose and high doses of venlafaxine in major depression.
Debonnel G; Saint-André E; Hébert C; de Montigny C; Lavoie N; Blier P
Int J Neuropsychopharmacol; 2007 Feb; 10(1):51-61. PubMed ID: 16690006
[TBL] [Abstract][Full Text] [Related]
22. Venlafaxine: discrepancy between in vivo 5-HT and NE reuptake blockade and affinity for reuptake sites.
Béïque JC; de Montigny C; Blier P; Debonnel G
Synapse; 1999 Jun; 32(3):198-211. PubMed ID: 10340630
[TBL] [Abstract][Full Text] [Related]
23. Effects of duloxetine and WAY100635 on pudendal inhibition of bladder overactivity in cats.
Reese J; Xiao Z; Schwen Z; Matsuta Y; Shen B; Wang J; Roppolo JR; de Groat WC; Tai C
J Pharmacol Exp Ther; 2014 Jun; 349(3):402-7. PubMed ID: 24667547
[TBL] [Abstract][Full Text] [Related]
24. Evidence of the dual mechanisms of action of venlafaxine.
Harvey AT; Rudolph RL; Preskorn SH
Arch Gen Psychiatry; 2000 May; 57(5):503-9. PubMed ID: 10807491
[TBL] [Abstract][Full Text] [Related]
25. Assessment of the serotonin and norepinephrine reuptake blocking properties of duloxetine in healthy subjects.
Turcotte JE; Debonnel G; de Montigny C; Hébert C; Blier P
Neuropsychopharmacology; 2001 May; 24(5):511-21. PubMed ID: 11282251
[TBL] [Abstract][Full Text] [Related]
26. Venlafaxine and its interaction with WAY 100635: effects on serotonergic unit activity and behavior in cats.
Bjorvatn B; Fornal CA; Martín FJ; Metzler CW; Jacobs BL
Eur J Pharmacol; 2000 Sep; 404(1-2):121-32. PubMed ID: 10980270
[TBL] [Abstract][Full Text] [Related]
27. Effects of sustained administration of the serotonin and norepinephrine reuptake inhibitor venlafaxine: II. In vitro studies in the rat.
Béïque J; de Montigny C; Blier P; Debonnel G
Neuropharmacology; 2000 Jul; 39(10):1813-22. PubMed ID: 10884562
[TBL] [Abstract][Full Text] [Related]
28. Duloxetine pharmacology: profile of a dual monoamine modulator.
Karpa KD; Cavanaugh JE; Lakoski JM
CNS Drug Rev; 2002; 8(4):361-76. PubMed ID: 12481192
[TBL] [Abstract][Full Text] [Related]
29. Reciprocal effects of combined administration of serotonin, noradrenaline and dopamine reuptake inhibitors on serotonin and dopamine levels in the rat prefrontal cortex: the role of 5-HT1A receptors.
Weikop P; Kehr J; Scheel-Krüger J
J Psychopharmacol; 2007 Nov; 21(8):795-804. PubMed ID: 17984160
[TBL] [Abstract][Full Text] [Related]
30. Effects of 5-HT(6) receptor blockade on the neurochemical outcome of antidepressant treatment in the frontal cortex of the rat.
Dawson LA; Li P
J Neural Transm (Vienna); 2003 Jun; 110(6):577-90. PubMed ID: 12768354
[TBL] [Abstract][Full Text] [Related]
31. Electrophysiological characterization of the effect of long-term duloxetine administration on the rat serotonergic and noradrenergic systems.
Rueter LE; De Montigny C; Blier P
J Pharmacol Exp Ther; 1998 May; 285(2):404-12. PubMed ID: 9580577
[TBL] [Abstract][Full Text] [Related]
32. Effects of different doses of venlafaxine on serotonin and norepinephrine reuptake in healthy volunteers.
Blier P; Saint-André E; Hébert C; de Montigny C; Lavoie N; Debonnel G
Int J Neuropsychopharmacol; 2007 Feb; 10(1):41-50. PubMed ID: 16690005
[TBL] [Abstract][Full Text] [Related]
33. Blockade of 5-hydroxytryptamine and noradrenaline uptake by venlafaxine: a comparative study with paroxetine and desipramine.
Béïque JC; de Montigny C; Blier P; Debonnel G
Br J Pharmacol; 1998 Oct; 125(3):526-32. PubMed ID: 9806336
[TBL] [Abstract][Full Text] [Related]
34. Affinities of venlafaxine and various reuptake inhibitors for the serotonin and norepinephrine transporters.
Béïque JC; Lavoie N; de Montigny C; Debonnel G
Eur J Pharmacol; 1998 May; 349(1):129-32. PubMed ID: 9669506
[TBL] [Abstract][Full Text] [Related]
35. Effect of chronic administration of duloxetine on serotonin and norepinephrine transporter binding sites in rat brain.
Gould GG; Javors MA; Frazer A
Biol Psychiatry; 2007 Jan; 61(2):210-5. PubMed ID: 16650830
[TBL] [Abstract][Full Text] [Related]
36. Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity.
Vaishnavi SN; Nemeroff CB; Plott SJ; Rao SG; Kranzler J; Owens MJ
Biol Psychiatry; 2004 Feb; 55(3):320-2. PubMed ID: 14744476
[TBL] [Abstract][Full Text] [Related]
37. Effects of duloxetine on norepinephrine and serotonin transporter activity in healthy subjects.
Chappell JC; Eisenhofer G; Owens MJ; Haber H; Lachno DR; Dean RA; Knadler MP; Nemeroff CB; Mitchell MI; Detke MJ; Iyengar S; Pangallo B; Lobo ED
J Clin Psychopharmacol; 2014 Feb; 34(1):9-16. PubMed ID: 24346757
[TBL] [Abstract][Full Text] [Related]
38. Effects of Duloxetine on Urethral Continence Reflex and Bladder Activity in Rats with Cerebral Infarction.
Miyazato M; Kitta T; Kaiho Y; Oshiro T; Saito S; Chancellor MB; de Groat WC; Yoshimura N
J Urol; 2015 Sep; 194(3):842-7. PubMed ID: 25804088
[TBL] [Abstract][Full Text] [Related]
39. Serotonin and Norepinephrine Reuptake Inhibitors.
Shelton RC
Handb Exp Pharmacol; 2019; 250():145-180. PubMed ID: 30838456
[TBL] [Abstract][Full Text] [Related]
40. What do we know about duloxetine's mode of action? Evidence from animals to humans.
Schuessler B
BJOG; 2006 May; 113 Suppl 1():5-9. PubMed ID: 16529563
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
